An examination of payer coverage for multiple sclerosis drugs shows variation in how these drugs are covered and in the evidence that payers review to make these decisions.
Jordan E. Anderson, BA
Advertisement
Articles by Jordan E. Anderson, BA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Cuts MACE Risk in Diabetes With Heart Disease
2
CVS Health Expands GLP-1 Access With $29 Visits, Lilly Deal
3
FDA Approves mFlusiva, the First mRNA-Based Influenza Vaccine
4
Q&A: Prepare for FDA Inspection on Compounded GLP-1s
5